Drugs / HAL-MPE1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02991885 | Dec 2016 → Apr 2019 | food allergy | HAL Allergy | Completed | No outcome recorded |
| Phase 1 | NCT02163018 | Jun 2014 → May 2015 | food allergy | HAL Allergy | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HAL-MPE1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02991885 ↗ |
| Known as | HAL-MPE1: modified peanut extract | “HAL-MPE1: modified peanut extract” NCT02163018 ↗ |
| Route | Subcutaneous | “for subcutaneous administration” NCT02163018 ↗ |